Kaiwen Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kaiwen Hu has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Quanwang Li
Oncology Department, Dongfang Hospital Beijing University of Chinese Medicine Beijing China
3 shared publicationsTian Zhou
Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, 100078, China
2 shared publicationsAntonio Cueto
1 shared publicationBaorang Zhu
Department of Tumor Minimally Invasive Treatment, The Fifth Medical Center Chinese PLA General Hospital Beijing China
1 shared publicationChongyi Lu
Animal Experiment Laboratory, AntiCancer Biotech (Beijing) Co., Ltd., No. 11 Huatong Road, Changping district, Beijing, China
1 shared publicationChuanbo Liu
Oncology Department, Dongfang Hospital Beijing University of Chinese Medicine Beijing China
1 shared publication
Latest Publications
- Open Access
- 14 December 2020
- Published by Wiley in Thoracic Cancer
- Vol. 12 (4) , 475-483
Co‐ablation versus cryoablation for the treatment of stage III–IV non‐small cell lung cancer: A prospective, noninferiority, randomized, controlled trial (RCT)
Background: This study compared a co‐ablation (CA) system, which is a novel ablation device, with an argon‐helium cryoablation (AHC) system. We aimed to compare the efficacy and safety of CA and AHC for the treatment of stage III–IV non‐small cell lung cancer (NSCLC).Methods: We conducted a multicenter randomized controlled trial (RCT) to determine whether CA was noninferior to AHC. The primary efficacy endpoints were the iceball coverage rate (ICR) and the disease control rate (DCR) one month after treatment. Noninferiority was declared if the lower limit of two‐sided 95% confidence interval (CI) was less than 10%. The ICR and DCR were identified by logistic regression. Treatment safety was assessed.Results: A total of 81 patients underwent randomization (41 assigned to the CA and 40 assigned to the AHC groups)and transthoracic ablation. The ICRs in the CA and AHC groups were 99.24% ± 2.18% and 98.66% ± 3.79%, respectively. Central lesions were associated with an increased risk of an incomplete ICR. The DCRs in the CA and AHC groups were 97.6% and 95%, respectively. A smaller lesion area in the CA group was significantly correlated with a better DCR. The rate of complications was 29.26% in the CA group and 30% in the AHC group. (P = 0.943). There was less probe usage per patient in the CA group.Conclusions: We determined that CA is noninferior to AHC in terms of efficacy and safety for the treatment of stage III–IV NSCLC. A smaller lesion area in the CA group was significantly correlated with a better DCR.Key points: CA was noninferior to AHC for stage III–IV NSCLC.
- 14 December 2020
- Published by Wiley in Thoracic Cancer
- Vol. 12 (4) , 475-483
Open AccessCo‐ablation versus cryoablation for the treatment of stage III–IV non‐small cell lung cancer: A prospective, noninferiority, randomized, controlled trial (RCT)
Background: This study compared a co‐ablation (CA) system, which is a novel ablation device, with an argon‐helium cryoablation (AHC) system. We aimed to compare the efficacy and safety of CA and AHC for the treatment of stage III–IV non‐small cell lung cancer (NSCLC).Methods: We conducted a multicenter randomized controlled trial (RCT) to determine whether CA was noninferior to AHC. The primary efficacy endpoints were the iceball coverage rate (ICR) and the disease control rate (DCR) one month after treatment. Noninferiority was declared if the lower limit of two‐sided 95% confidence interval (CI) was less than 10%. The ICR and DCR were identified by logistic regression. Treatment safety was assessed.Results: A total of 81 patients underwent randomization (41 assigned to the CA and 40 assigned to the AHC groups)and transthoracic ablation. The ICRs in the CA and AHC groups were 99.24% ± 2.18% and 98.66% ± 3.79%, respectively. Central lesions were associated with an increased risk of an incomplete ICR. The DCRs in the CA and AHC groups were 97.6% and 95%, respectively. A smaller lesion area in the CA group was significantly correlated with a better DCR. The rate of complications was 29.26% in the CA group and 30% in the AHC group. (P = 0.943). There was less probe usage per patient in the CA group.Conclusions: We determined that CA is noninferior to AHC in terms of efficacy and safety for the treatment of stage III–IV NSCLC. A smaller lesion area in the CA group was significantly correlated with a better DCR.Key points: CA was noninferior to AHC for stage III–IV NSCLC.
- 1 April 2017
- Published by Elsevier in Cryobiology
- Vol. 75, 80-87
0 °C is better?- Thawing temperature optimization study for cancer cryoablation in a mouse model with green fluorescent protein-labeled Lewis lung cancer
- 1 April 2017
- Published by Elsevier in Cryobiology
- Vol. 75, 80-87
0 °C is better?- Thawing temperature optimization study for cancer cryoablation in a mouse model with green fluorescent protein-labeled Lewis lung cancer
- 1 August 2015
- Published by Elsevier in Cryobiology
- Vol. 71 (1) , 40-46
Non-extended cryoablation could be a new strategy in lung cancer management: An experiment on green fluorescent protein-labeled Lewis lung cancer-bearing mice
- 1 August 2015
- Published by Elsevier in Cryobiology
- Vol. 71 (1) , 40-46
Non-extended cryoablation could be a new strategy in lung cancer management: An experiment on green fluorescent protein-labeled Lewis lung cancer-bearing mice
- Open Access
- 1 January 2015
- Published by Open Access Text Pvt, Ltd. in Integrative Cancer Science and Therapeutics
- Vol. 2 (5)
A case of unresectable small cell lung cancermore than 7 years of survival treated with cryoablation and low dose chemotherapy
OA Text is an independent open-access scientific publisher showcases innovative research and ideas aimed at improving health by linking research and practice to the benefit of society.
- 1 January 2015
- Published by Open Access Text Pvt, Ltd. in Integrative Cancer Science and Therapeutics
- Vol. 2 (5)
Open AccessA case of unresectable small cell lung cancermore than 7 years of survival treated with cryoablation and low dose chemotherapy
OA Text is an independent open-access scientific publisher showcases innovative research and ideas aimed at improving health by linking research and practice to the benefit of society.